Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Loral Space & Communications -- Ignore unavailable to you. Want to Upgrade?

To: Jeff Vayda who wrote (5583)	3/24/1999 11:27:00 AM
From: brian h	Respond to of 10852

Jeff, I agree with your comments. I am against the poison pill also. Though do not tough my G*. It should stay as is until operation. I do not want it being bought. However, I do think LOR need more help to get other things going. It was too weak in term of financing support. Brina H.

To: Jeff Vayda who wrote (5583)	3/24/1999 11:37:00 AM
From: Rocket Scientist	Read Replies (1) \| Respond to of 10852

1. The pay raise for Schwartz was effective 3/1/98, when the stock was much higher than it is now, and pre-China, pre-Zenit; I suppose the paper losses he's incurred as a result of the above outweigh by a factor of at least 10 his increase in salary. Anyway, it's pretty clear to me that Schwartz and the other top guns got big raises to preserve parity with G. Clark, who was hired in (early last year) at a big premium with respect to M.Targoff's old salary. Maybe Clark is overpaid, but I assume the company did some DD before hiring him at the price it paid. 2. Regarding the new preferred stock, It's not clear the main purpose is as a poison pill as opposed to a normal financing tool. Anyway, I tend to favor anything that would make Loral harder to take over at this point. Regards, RS